Platelet function in patients with diabetes mellitus: From a theoretical to a practical perspective

International Journal of Endocrinology

Volumn 2011, Issue , 2011, Pages

  Kakouros, Nicholaos ^a   Rade, Jeffrey J ^a   Kourliouros, Antonios ^b   Resar, Jon R ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; CANGRELOR; CD40 LIGAND; CILOSTAZOL; CLOPIDOGREL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ELINOGREL; FIBRIN; FIBRINOGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PLACEBO; PRASUGREL; PROTEIN KINASE C; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; SULFONYLUREA; TICAGRELOR; TICLOPIDINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMPETITIVE INHIBITION; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVATION; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART BLOCK; HEART DEATH; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LOADING DRUG DOSE; MAINTENANCE THERAPY; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THEORETICAL STUDY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE HYPERREACTIVITY; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS;

EID: 80053508880     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2011/742719     Document Type: Review

References (114)

1. Centers for Disease Control and Prevention, Atlanta G. A., National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 Department of Health and Human Services 2011 Centers for Disease Control and Prevention
2. Shaw J. E., Sicree R. A., Zimmet P. Z., Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Research and Clinical Practice 2010 87 1 4 14
3. Laakso M., Lehto S., Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance Atherosclerosis 1998 137 S65 S73
4. Kannel W. B., D'Agostino R. B., Wilson P. W. F., Belanger A. J., Gagnon D. R., Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience American Heart Journal 1990 120 3 672 676 (Pubitemid 20312600)
5. Maiello M., Boeri D., Podesta F., Cagliero E., Vichi M., Odetti P., Adezati L., Lorenzi M., Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose Diabetes 1992 41 8 1009 1015
6. Ang L., Palakodeti V., Khalid A., Tsimikas S., Idrees Z., Tran P., Clopton P., Zafar N., Bromberg-Marin G., Keramati S., Mahmud E., Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel Journal of the American College of Cardiology 2008 52 13 1052 1059
7. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A., Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata diabetes study Diabetes Care 1999 22 6 920 924 (Pubitemid 29241045)
8. Lefbvre P. J., Glucose metabolism and the postprandial state European Journal of Clinical Investigation 1999 29 supplement 2 1 6
9. Yngen M., stenson C. G., Li N., Hjemdahl P., Wallén N. H., Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus Blood Coagulation and Fibrinolysis 2001 12 2 109 116 (Pubitemid 32234818)
10. Undas A., Wiek I., Stpie E., Zmudka K., Tracz W., Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome Diabetes Care 2008 31 8 1590 1595
11. Vaidyula V. R., Rao A. K., Mozzoli M., Homko C., Cheung P., Boden G., Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand Diabetes 2006 55 1 202 208 (Pubitemid 43343316)
12. Keating F. K., Sobel B. E., Schneider D. J., Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus American Journal of Cardiology 2003 92 11 1362 1365 (Pubitemid 37431156)
13. Assert R., Scherk G., Bumbure A., Pirags V., Schatz H., Pfeiffer A. F. H., Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro Diabetologia 2001 44 2 188 195 (Pubitemid 32156203)
14. Yncen M., Norhammar A., Hjemdahl P., Wallén N. H., Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty Diabetes and Vascular Disease Research 2006 3 1 52 56 (Pubitemid 43877254)
15. Muhlestein J. B., Anderson J. L., Horne B. D., Lavasani F., Allen Maycock C. A., Bair T. L., Pearson R. R., Carlquist J. F., Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention American Heart Journal 2003 146 2 351 358 (Pubitemid 36951783)
16. Corpus R. A., George P. B., House J. A., Dixon S. R., Ajluni S. C., Devlin W. H., Timmis G. C., Balasubramaniam M., O'Neill W. W., Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention Journal of the American College of Cardiology 2004 43 1 8 14 (Pubitemid 38045906)
17. Wautier J. L., Schmidt A. M., Protein glycation: a firm link to endothelial cell dysfunction Circulation Research 2004 95 3 233 238 (Pubitemid 39056283)
18. Wang Y., Beck W., Deppisch R., Marshall S. M., Hoenich N. A., Thompson M. G., Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors American Journal of PhysiologyCell Physiology 2007 293 1 C328 C336
19. Winocour P. D., Watala C., Perry D. W., Kinlough-Rathbone R. L., Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins Thrombosis and Haemostasis 1992 68 5 577 582
20. Watala C., Boncer M., Golaski J., Koziokiewicz W., Trojanowski Z., Walkowiak B., Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus European Journal of Haematology 1998 61 5 319 326 (Pubitemid 28551681)
21. Tschoepe D., The activated megakaryocyteplatelet-system in vascular disease: focus on diabetes Seminars in Thrombosis and Hemostasis 1995 21 2 152 160
22. Ferreira I. A., Mocking A. I. M., Feijge M. A. H., Gorter G., Van Haeften T. W., Heemskerk J. W. M., Akkerman J. W. N., Platelet inhibition by insulin is absent in type 2 diabetes mellitus Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 2 417 422 (Pubitemid 43732209)
23. Hechler B., Cattaneo M., Gachet C., The P2 receptors in platelet function Seminars in Thrombosis and Hemostasis 2005 31 2 150 161 (Pubitemid 40605190)
24. Alexandru N., Popov D., Sbarcea A., Amuzescu M., Platelet free cytosolic calcium concentration during ageing of type 2 diabetic patients Platelets 2007 18 7 473 480 (Pubitemid 350034855)
25. Pedreo J., Hurt-Camejo E., Wiklund O., Badimn L., Masana L., Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles Metabolism 2000 49 7 942 949 (Pubitemid 30483450)
26. Calkin A. C., Drew B. G., Ono A., Duffy S. J., Gordon M. V., Schoenwaelder S. M., Sviridov D., Cooper M. E., Kingwell B. A., Jackson S. P., Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux Circulation 2009 120 21 2095 2104
27. Ferretti G., Rabini R. A., Bacchetti T., Vignini A., Salvolini E., Ravaglia F., Curatola G., Mazzanti L., Glycated low density lipoproteins modify platelet properties: a compositional and functional study Journal of Clinical Endocrinology and Metabolism 2002 87 5 2180 2184 (Pubitemid 34521506)
28. Falcon C., Pfliegler G., Deckmyn H., Vermylen J., The platelet insulin receptor: detection, partial characterizaztion, and search for a function Biochemical and Biophysical Research Communications 1988 157 3 1190 1196 (Pubitemid 19025983)
29. Hwang D. L., Yen C. F., Nadler J. L., Insulin increases intracellular magnesium transport in human platelets Journal of Clinical Endocrinology and Metabolism 1993 76 3 549 553 (Pubitemid 23086464)
30. Trovati M., Anfossi G., Massucco P., Mattiello L., Costamagna C., Piretto V., Mularoni E., Cavalot F., Bosia A., Ghigo D., Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine- 3′, 5′ -cyclic monophosphate and adenosine-3',5'-cyclic monophosphate Diabetes 1997 46 5 742 749 (Pubitemid 27188249)
31. Ferreira I. A., Eybrechts K. L., Mocking A. I. M., Kroner C., Akkerman J. W. N., IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi Journal of Biological Chemistry 2004 279 5 3254 3264 (Pubitemid 38140559)
32. Hunter R. W., Hers I., Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function Journal of Thrombosis and Haemostasis 2009 7 12 2123 2130
33. Hers I., Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3K pathway Blood 2007 110 13 4243 4252 (Pubitemid 351377788)
34. Hiramatsu K., Nozaki H., Arimori S., Reduction of platelet aggregation induced by euglycaemic insulin clamp Diabetologia 1987 30 5 310 313 (Pubitemid 17083699)
35. Trovati M., Anfossi G., Cavalot F., Massucco P., Mularoni E., Emanuelli G., Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo Diabetes 1988 37 6 780 786 (Pubitemid 19043187)
36. Westerbacka J., Yki-Jrvinen H., Turpeinen A., Rissanen A., Vehkavaara S., Syrjl M., Lassila R., Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 1 167 172 (Pubitemid 34076249)
37. Murakami T., Horigome H., Tanaka K., Nakata Y., Ohkawara K., Katayama Y., Matsui A., Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity Thrombosis Research 2007 119 1 45 53 (Pubitemid 44716205)
38. Kahn B. B., Flier J. S., Obesity and insulin resistance Journal of Clinical Investigation 2000 106 4 473 481 (Pubitemid 30666380)
39. Basili S., Pacini G., Guagnano M. T., Manigrasso M. R., Santilli F., Pettinella C., Ciabattoni G., Patrono C., Dav G., Insulin resistance as a determinant of platelet activation in obese women Journal of the American College of Cardiology 2006 48 12 2531 2538 (Pubitemid 44881227)
40. Dav G., Guagnano M. T., Ciabattoni G., Basili S., Falco A., Marinopiccoli M., Nutini M., Sensi S., Patrono C., Platelet activation in obese women: role of inflammation and oxidant stress Journal of the American Medical Association 2002 288 16 2008 2014 (Pubitemid 35204691)
41. Ishida M., Ishida T., Ono N., Matsuura H., Watanabe M., Kajiyama G., Kambe M., Oshima T., Effects of insulin on calcium metabolism and platelet aggregation Hypertension 1996 28 2 209 212 (Pubitemid 26322791)
42. Angiolillo D. J., Bernardo E., Ramrez C., Costa M. A., Sabaté M., Jimenez-Quevedo P., Hernndez R., Moreno R., Escaned J., Alfonso F., Bauelos C., Bass T. A., Macaya C., Fernandez-Ortiz A., Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment Journal of the American College of Cardiology 2006 48 2 298 304 (Pubitemid 44026661)
43. Betteridge D. J., El Tahir K. E. H., Reckless J. P. D., Williams K., Platelets from diabetic subjects show diminished sensitivity to prostacyclin European Journal of Clinical Investigation 1982 12 5 395 398 (Pubitemid 12000931)
44. Anfossi G., Mularoni E. M., Burzacca S., Ponziani M. C., Massucco P., Mattiello L., Cavalot F., Trovati M., Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM Diabetes Care 1998 21 1 121 126 (Pubitemid 28030398)
45. Vaidyula V. R., Boden G., Rao A. K., Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects Platelets 2006 17 8 577 585 (Pubitemid 44837728)
46. Redondo P. C., Jardin I., Hernndez-Cruz J. M., Pariente J. A., Salido G. M., Rosado J. A., Hydrogen peroxide and peroxynitrite enhance Ca2+ mobilization and aggregation in platelets from type 2 diabetic patients Biochemical and Biophysical Research Communications 2005 333 3 794 802 (Pubitemid 40854229)
47. Freedman J. E., Oxidative stress and platelets Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 3 s11 s16
48. Jardn I., Redondo P. C., Salido G. M., Pariente J. A., Rosado J. A., Endogenously generated reactive oxygen species reduce PMCA activity in platelets from patients with non-insulin-dependent diabetes mellitus Platelets 2006 17 5 283 288 (Pubitemid 44277692)
49. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J. P., Colette C., Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes Journal of the American Medical Association 2006 295 14 1681 1687
50. Dav G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., Pennese E., Vitacolonna E., Bucciarelli T., Costantini F., Capani F., Patrono C., In vivo formation of 8-iso-prostaglandin and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation Circulation 1999 99 2 224 229 (Pubitemid 29056363)
51. Sampson M. J., Gopaul N., Davies I. R., Hughes D. A., Carrier M. J., Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes Diabetes Care 2002 25 3 537 541 (Pubitemid 41103349)
52. Schaeffer G., Wascher T. C., Kostner G. M., Graier W. F., Alterations in platelet CA2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production Diabetologia 1999 42 2 167 176 (Pubitemid 29064238)
53. Schmidt A. M., Yan S. D., Wautier J. L., Stern D., Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis Circulation Research 1999 84 5 489 497 (Pubitemid 29138585)
54. Spinetti G., Kraenkel N., Emanueli C., Madeddu P., Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies Cardiovascular Research 2008 78 2 265 273 (Pubitemid 351556106)
55. Schneider D. J., Factors contributing to increased platelet reactivity in people with diabetes Diabetes Care 2009 32 4 525 527
56. Belostocki K., Pricop L., Redecha P. B., Aydin A., Leff L., Harrison M. J., Salmon J. E., Infliximab treatment shifts the balance between stimulatory and inhibitory Fc receptor type II isoforms on neutrophils in patients with rheumatoid arthritis Arthritis and Rheumatism 2008 58 2 384 388 (Pubitemid 351294873)
57. Tschoepe D., Roesen P., Esser J., Schwippert B., Nieuwenhuis H. K., Kehrel B., Gries F. A., Large platelets circulate in an activated state in diabetes mellitus Seminars in Thrombosis and Hemostasis 1991 17 4 433 438
58. Guthikonda S., Lev E. I., Patel R., Delao T., Bergeron A. L., Dong J. F., Kleiman N. S., Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin Journal of Thrombosis and Haemostasis 2007 5 3 490 496 (Pubitemid 46680680)
59. Guthikonda S., Alviar C. L., Vaduganathan M., Arikan M., Tellez A., DeLao T., Granada J. F., Dong J. F., Kleiman N. S., Lev E. I., Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease Journal of the American College of Cardiology 2008 52 9 743 749
60. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients British Medical Journal 2002 324 7329 71 86
61. Beigel R., Hod H., Fefer P., Asher E., Novikov I., Shenkman B., Savion N., Varon D., Matetzky S., Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction American Journal of Cardiology 2011 107 3 339 342
62. Krasopoulos G., Brister S. J., Beattie W. S., Buchanan M. R., Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 2008 336 7637 195 198 (Pubitemid 351212675)
63. Eikelboom J. W., Hirsh J., Weitz J. I., Johnston M., Yi Q., Yusuf S., Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 2002 105 14 1650 1655 (Pubitemid 34298607)
64. Breet N. J., Van Werkum J. W., Bouman H. J., Kelder J. C., Ten Berg J. M., Hackeng C. M., High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events Journal of Thrombosis and Haemostasis 2010 8 10 2140 2148
65. Reny J. L., De Moerloose P., Dauzat M., Fontana P., Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis Journal of Thrombosis and Haemostasis 2008 6 3 444 450 (Pubitemid 351280111)
66. Fateh-Moghadam S., Plckinger U., Cabeza N., Htun P., Reuter T., Ersel S., Gawaz M., Dietz R., Bocksch W., Prevalence of aspirin resistance in patients with type 2 diabetes Acta Diabetologica 2005 42 2 99 103 (Pubitemid 40881115)
67. Mehta S. S., Silver R. J., Aaronson A., Abrahamson M., Goldfine A. B., Comparison of Aspirin resistance in type 1 versus type 2 diabetes mellitus American Journal of Cardiology 2006 97 4 567 570 (Pubitemid 43190052)
68. Becker D. M., Segal J., Vaidya D., Yanek L. R., Herrera-Galeano J. E., Bray P. F., Moy T. F., Becker L. C., Faraday N., Sex differences in platelet reactivity and response to low-dose aspirin therapy Journal of the American Medical Association 2006 295 12 1420 1427
69. Gluckman T. J., McLean R. C., Schulman S. P., Kickler T. S., Shapiro E. P., Conte J. V., McNicholas K. W., Segal J. B., Rade J. J., Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery Journal of the American College of Cardiology 2011 57 9 1069 1077
70. Chung A. W., Jurasz P., Hollenberg M. D., Radomski M. W., Mechanisms of action of proteinase-activated receptor agonists on human platelets British Journal of Pharmacology 2002 135 5 1123 1132 (Pubitemid 34259112)
71. Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation New England Journal of Medicine 2001 345 7 494 502 (Pubitemid 32758501)
72. Bhatt D. L., Fox K. A. A., Hacke W., Berger P. B., Black H. R., Boden W. E., Cacoub P., Cohen E. A., Creager M. A., Easton J. D., Flather M. D., Haffner S. M., Hamm C. W., Hankey G. J., Johnston S. C., Mak K. H., Mas J. L., Montalescot G., Pearson T. A., Steg P. G., Steinhubl S. R., Weber M. A., Brennan D. M., Fabry-Ribaudo L., Booth J., Topol E. J., Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events New England Journal of Medicine 2006 354 16 1706 1717
73. Geisler T., Langer H., Wydymus M., Ghring K., Zrn C., Bigalke B., Stellos K., May A. E., Gawaz M., Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation European Heart Journal 2006 27 20 2420 2425 (Pubitemid 44522148)
74. Gurbel P. A., Bliden K. P., Samara W., Yoho J. A., Hayes K., Fissha M. Z., Tantry U. S., Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study Journal of the American College of Cardiology 2005 46 10 1827 1832 (Pubitemid 41579803)
75. Hochholzer W., Trenk D., Bestehorn H. P., Fischer B., Valina C. M., Ferenc M., Gick M., Caputo A., Bttner H. J., Neumann F. J., Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronaryc stent placement Journal of the American College of Cardiology 2006 48 9 1742 1750 (Pubitemid 44648629)
76. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., Hod H., Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 2004 109 25 3171 3175
77. Breet N. J., Van Werkum J. W., Bouman H. J., Kelder J. C., Ruven H. J. T., Bal E. T., Deneer V. H., Harmsze A. M., Van Der Heyden J. A. S., Rensing B. J. W. M., Suttorp M. J., Hackeng C. M., Ten Berg J. M., Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation Journal of the American Medical Association 2010 303 8 754 762
78. Park K. W., Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovascular Therapeutics. In press
79. Angiolillo D. J., Fernandez-Ortiz A., Bernardo E., Ramrez C., Sabaté M., Jimenez-Quevedo P., Hernndez R., Moreno R., Escaned J., Alfonso F., Bauelos C., Costa M. A., Bass T. A., Macaya C., Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 2005 54 8 2430 2435 (Pubitemid 41134272)
80. Angiolillo D. J., Shoemaker S. B., Desai B., Yuan H., Charlton R. K., Bernardo E., Zenni M. M., Guzman L. A., Bass T. A., Costa M. A., Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study Circulation 2007 115 6 708 716 (Pubitemid 46294761)
81. Mangiacapra F., Patti G., Peace A., Gatto L., Vizzi V., Ricottini E., D'Ambrosio A., Muller O., Barbato E., Di Sciascio G., Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention American Journal of Cardiology 2010 106 5 619 623
82. Mangiacapra F., Peace A. J., Wijns W., Barbato E., Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel Journal of Thrombosis and Thrombolysis 2011 1 5
83. Harmsze A. M., Van Werkum J. W., Moral F., Ten Berg J. M., Hackeng C. M., Klungel O. H., De Boer A., Deneer V. H.M., Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients Platelets 2011 22 2 98 102
84. Goto S., Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding Atherosclerosis Supplements 2005 6 4 3 11 (Pubitemid 43263084)
85. Jeong Y. H., Lee S. W., Choi B. R., Kim I. S., Seo M. K., Kwak C. H., Hwang J. Y., Park S. W., Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity. results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study Journal of the American College of Cardiology 2009 53 13 1101 1109
86. Angiolillo D. J., Capranzano P., Goto S., Aslam M., Desai B., Charlton R. K., Suzuki Y., Box L. C., Shoemaker S. B., Zenni M. M., Guzman L. A., Bass T. A., A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study European Heart Journal 2008 29 18 2202 2211
87. Lee S. W., Park S. W., Yun S. C., Kim Y. H., Park D. W., Kim W. J., Lee J. Y., Lee C. W., Hong M. K., Kim J. J., Park S. J., Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry) American Heart Journal 2010 159 2 284.e1 291.e1
88. Suh J. W., Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial Journal of the American College of Cardiology 2011 57 280 289
89. Park K. W., Park J. J., Lee S. -P., Oh I. -Y., Suh J. -W., Yang H. -M., Lee H. -Y., Kang H. -J., Cho Y. -S., Koo B. -K., Youn T. -J., Chae I. -H., Choi D. -J., Oh B. -H., Park Y. -B., Kim H. -S., Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial Heart 2011 97 8 641 647
90. Roffi M., Early invasive strategy in the diabetic patient with non-ST-segment elevation acute coronary syndromes European Heart Journal, Supplements 2005 7 K19 K22
91. Peterson E. D., Pollack C. V., Roe M. T., Parsons L. S., Littrell K. A., Canto J. G., Barron H. V., Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the national registry of myocardial infarction 4 Journal of the American College of Cardiology 2003 42 1 45 53 (Pubitemid 36760759)
92. Radke P. W., Schunkert H., Diabetics with acute coronary syndrome: advances, challenges, and uncertainties European Heart Journal 2010 31 24 2971 2973
93. Jakubowski J. A., Winters K. J., Naganuma H., Wallentin L., Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovascular Drug Reviews 2007 25 4 357 374 (Pubitemid 350233359)
94. Wiviott S. D., Trenk D., Frelinger A. L., O'Donoghue M., Neumann F. J., Michelson A. D., Angiolillo D. J., Hod H., Montalescot G., Miller D. L., Jakubowski J. A., Cairns R., Murphy S. A., McCabe C. H., Antman E. M., Braunwald E., Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial Circulation 2007 116 25 2923 2932 (Pubitemid 350291199)
95. Wiviott S. D., Braunwald E., Angiolillo D. J., Meisel S., Dalby A. J., Verheugt F. W. A., Goodman S. G., Corbalan R., Purdy D. A., Murphy S. A., McCabe C. H., Antman E. M., Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Circulation 2008 118 16 1626 1636
96. Kushner F. G., 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (Updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 2009 120 2271 2306
97. Berger J. S., Roe M. T., Gibson C. M., Kilaru R., Green C. L., Melton L., Blankenship J. D., Metzger D. C., Granger C. B., Gretler D. D., Grines C. L., Huber K., Zeymer U., Buszman P., Harrington R. A., Armstrong P. W., Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) American Heart Journal 2009 158 6 998.e1 1004.e1
98. Rao S. V., A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions Proceedings of the European Society of Cardiology Congress 2010 Stockholm, Sweden
99. Mega J. L., Close S. L., Wiviott S. D., Shen L., Walker J. R., Simon T., Antman E. M., Braunwald E., Sabatine M. S., Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis The Lancet 2010 376 9749 1312 1319
100. Gurbel P. A., Bliden K. P., Butler K., Antonino M. J., Wei C., Teng R., Rasmussen L., Storey R. F., Nielsen T., Eikelboom J. W., Sabe-Affaki G., Husted S., Kereiakes D. J., Henderson D., Patel D. V., Tantry U. S., Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 2010 121 10 1188 1199
101. Gurbel P. A., Bliden K. P., Butler K., Tantry U. S., Gesheff T., Wei C., Teng R., Antonino M. J., Patil S. B., Karunakaran A., Kereiakes D. J., Parris C., Purdy D., Wilson V., Ledley G. S., Storey R. F., Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 2009 120 25 2577 2585
102. Wallentin L., Becker R. C., Budaj A., Cannon C. P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K. W., Scirica B. M., Skene A., Steg P. G., Storey R. F., Harrington R. A., Ticagrelor versus clopidogrel in patients with acute coronary syndromes New England Journal of Medicine 2009 361 11 1045 1057
103. James S., Angiolillo D. J., Cornel J. H., Erlinge D., Husted S., Kontny F., Maya J., Nicolau J. C., Spinar J., Storey R. F., Stevens S. R., Wallentin L., Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial European Heart Journal 2010 31 24 3006 3016
104. Lotrionte M., Biondi-Zoccai G. G. L., Agostoni P., Abbate A., Angiolillo D. J., Valgimigli M., Moretti C., Meliga E., Cuisset T., Alessi M. C., Montalescot G., Collet J. P., Di Sciascio G., Waksman R., Testa L., Sangiorgi G., Laudito A., Trevi G. P., Sheiban I., Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention American Journal of Cardiology 2007 100 8 1199 1206
105. Price M. J., Berger P. B., Teirstein P. S., Tanguay J. -F., Angiolillo D. J., Spriggs D., Puri S., Robbins M., Garratt K. N., Bertrand O. F., Stillablower M. E., Aragon J. R., Kandzari D. E., Stinis C. T., Lee M. S., Manoukian S. V., Cannon C. P., Schork N. J., Topol E. J., Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial Journal of the American Medical Association 2011 305 11 1097 1105
106. Chintala M., Shimizu K., Ogawa M., Yamaguchi H., Doi M., Jensen P., Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease Journal of Pharmacological Sciences 2008 108 4 433 438
107. Morrow D. A., Scirica B. M., Fox K. A. A., Berman G., Strony J., Veltri E., Bonaca M. P., Fish P., McCabe C. H., Braunwald E., Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA P)-TIMI 50 trial American Heart Journal 2009 158 3 335.e3 341.e3
108. The TRA-CER Executive and Steering Committees, The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial: study design and rationale American Heart Journal 2009 158 327.e4 334.e4
109. Goto S., Ogawa H., Takeuchi M., Flather M. D., Bhatt D. L., Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease European Heart Journal 2010 31 21 2601 2613
110. Hennerici M. G., Bots M. L., Ford I., Laurent S., Touboul P. J., Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial Cardiovascular Drugs and Therapy 2010 24 2 175 180
111. Chen J., Bhatt D. L., Dunn E. S., Shi C., Caro J. J., Mahoney E. M., Gabriel S., Jackson J. D., Topol E. J., Cohen D. J., Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial Value in Health 2009 12 6 872 879
112. Dasgupta A., Steinhubl S. R., Bhatt D. L., Berger P. B., Shao M., Mak K.
113. Pignone M., Williams C. D., Aspirin for primary prevention of cardiovascular disease in diabetes mellitus Nature Reviews Endocrinology 2010 6 11 619 628
114. Pignone M., Alberts M. J., Colwell J. A., Cushman M., Inzucchi S. E., Mukherjee D., Rosenson R. S., Williams C. D., Wilson P. W., Kirkman M. S., Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the american diabetes association, a scientific statement of the american heart association, and an expert consensus document of the american college of cardiology foundation Circulation 2010 121 24 2694 2701